Journal of Endocrinological Investigation

, Volume 24, Issue 6, pp 454–459 | Cite as

Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male

  • Franco Forloni
  • M. Giovilli
  • C. Pecis
  • E. Bortolani
  • A. Preziosi
  • M. E. Barzaghi
  • D. Corti
  • P. Beck-Peccoz
Case Report


We describe an unusual case of bilateral breast cancer synchronous with pituitary macroprolactinoma in a young male. Up to date, only very few of such cases have been described worldwide and to our knowledge this is the first one in which both breast cancer and pituitary macroadenoma have been found together at the time of presentation. A 45-year-old male was diagnosed as having a pituitary macroprolactinoma and bilateral breast cancer on the basis of hypogonadism (testosterone 2.9 pmol/l) with very high levels of prolactin (33,100 U/l), typical neuroradiologic finding of a pituitary macroadenoma, marked bilateral gynecomastia with mammographic pattern highly suspected for cancer and subsequent hystological confirmation. Bilateral mastectomy was performed and medical therapy with bromocriptine 10 mg/day was started. After 2-year follow-up the patient is disease-free. Hormonal, neuroradiological and oncological patterns are all negative or markedly improved. We stress the importance of prolactin for its possible biological effects on breast cancer induction or growth. Moreover in any case of hyperprolactinemia we suggest a mammographic examination and, in the case of breast cancer, at least a baseline hormonal profile.


Prolactin pituitary macroadenoma bilateral breast cancer male breast cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olsson H., Ramstam J. Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. J. Natl. Cancer Inst. 1988, 80: 679–683.PubMedCrossRefGoogle Scholar
  2. 2.
    Volm M.D., Talamonti M.S., Thangavelu M., Gradishar W.J. Pituitary adenoma and bilateral male breast cancer: an unusual association. J. Surg. Oncol. 1997, 64: 74–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Giaume M., Calcina G.G., Briglia R. Carcinoma bilaterale della mammella maschile. Oncologia, Minerva Medica, 1986, 77: 989–993.Google Scholar
  4. 4.
    Crichlow R.W., Galt S.W. Male breast cancer. Surg. Clin. North Am. 1990, 70: 1165–1177.PubMedGoogle Scholar
  5. 5.
    Olsson H., Alm P., Kristoffersson U., Landin-Olsson M. Hypophyseal tumour and gynecomastia preceding bilateral breast cancer development in a man. Cancer 1984, 53: 1974–1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Haga S., Watanabe O., Shimizu T., Iida T., Imamura H., Kajiwara T., Fujibayashi M. Breast cancer in a male with prolactinoma. Surg. Today 1993, 23: 251–255.PubMedCrossRefGoogle Scholar
  7. 7.
    Crichlow R.W. Carcinoma of the male breast. Surg. Gynecol. Obstet. 1972, 134: 1011–1019.PubMedGoogle Scholar
  8. 8.
    Calabresi E., De Guili G., Becciolini A., Giannotti P., Lombardo G., Serio M. Plasma estrogens and androgens in male breast cancer. J. Steroid Biochem. 1976, 7: 605–609.PubMedCrossRefGoogle Scholar
  9. 9.
    Hayward J. Hormones and human breast cancer. Springer Verlag, Berlin, 1970, p. 113.Google Scholar
  10. 10.
    Bavafa S., Reyes C.V., Choudhuri A.M. Male breast carcinoma: an updated experience at a veterans administration hospital and review of the literature. J. Surg. Oncol. 1983, 24: 41–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Mioduszewski O., Woszarowski T., Gorski C. The influence of hormones on breast cancer in vitro in relation to the clinical course of the disease. In: Forrest A.P.M., Kunkler P.B. (Eds.), Prognostic factors in breast cancer. Livingstone, Edimburgh, 1968. p. 347.Google Scholar
  12. 12.
    Mertani H.C., Garcia-Caballero T., Lambert A., Gerard F., Palayer C., Boutin J.M., Vonderhaar B.K., Waters M.J., Lobie P.E., Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer 1998, 79: 202–211.PubMedCrossRefGoogle Scholar
  13. 13.
    Ortega J.V., Longridge N.S. Fracture of the sellae turcicae. Injury 1974, 6: 335–337.CrossRefGoogle Scholar
  14. 14.
    Crampton M.R. Hypotalamic lesions following closed head injury. Brain 1971, 94: 165–172.CrossRefGoogle Scholar
  15. 15.
    Welsh C.W., Nagasawa H. Prolactin and murine mammary tumorigenesis. Cancer Res. 1977, 37: 951–963.Google Scholar
  16. 16.
    Reynolds C., Montone K.T., Powell C.M., Tomaszewski J.E., Clevenger C.V. Expression of prolactin and its receptor in human breast carcinoma. Epidemiology 1997, 138: 5555–5560.Google Scholar
  17. 17.
    Vonderhaar B.K. Prolactin involvement in breast cancer. Endocr. Rel. Cancer 1999, 6: 389–404.CrossRefGoogle Scholar
  18. 18.
    Surmacz E. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5: 95–105.PubMedCrossRefGoogle Scholar
  19. 19.
    Strain A.J., Ingleton P.M. Growth hormone- and prolactin-induced release of insulin-like growth factor by isolated rat hepatocytes. Biochem. Soc. Trans. 1990, 18: 1206–1210.PubMedGoogle Scholar
  20. 20.
    Fruchtman S., Jackson L., Borski R. Insulin-like growth factor-I disparately regulates prolactin and growth hormone synthesis and secretion: studies using the teleost pituitary model. Endocrinology 2000, 141: 2886–2894.PubMedGoogle Scholar
  21. 21.
    Atkin S.L., Landolt A.M., Foy P., Jeffreys R.V., Hipkin L., White M.C. Effects of insulin-like growth factor-I on growth hormone and prolactin secretion and cell proliferation of human somatotrophinomas and prolactinomas in vitro. Clin. Endocrinol. (Oxf.) 1994, 41: 503–509.CrossRefGoogle Scholar
  22. 22.
    Campbell P.G., Skaar T.C., Vega J.R., Baumrucker C.R. Secretion of insulin-like growth factor-I (IGF-I) and IGF-binding proteins from bovine mammary tissue in vitro. J. Endocrinol. 1991, 128: 219–228.PubMedCrossRefGoogle Scholar
  23. 23.
    Wennbo H., Gebre-Medhin M., Gritli-Linde A., Ohlsson C., Isaksson O.G., Tornell G. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. 1997, 100: 2744–2751.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Barni S., Lissoni P., Brivio F., Fumagalli L., Merlini D., Cataldo M., Rovelli F., Tancini G. Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994, 80: 212–215.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2001

Authors and Affiliations

  • Franco Forloni
    • 1
  • M. Giovilli
    • 2
  • C. Pecis
    • 2
  • E. Bortolani
    • 2
  • A. Preziosi
    • 2
  • M. E. Barzaghi
    • 2
  • D. Corti
    • 3
  • P. Beck-Peccoz
    • 4
  1. 1.Department of MedicinaTreviglio/Caravaggio HospitalTreviglio, BergamoItaly
  2. 2.Department of SurgeryTreviglio/Caravaggio HospitalTreviglioItaly
  3. 3.Department of Pathological ServiceTreviglio/Caravaggio HospitalTreviglioItaly
  4. 4.Institute of Endocrine SciencesUniversity of Milan, Ospedale Maggiore IRCCSMilanItaly

Personalised recommendations